Algert Global LLC Reduces Stake in Twist Bioscience Co. (NASDAQ:TWST)

Algert Global LLC lowered its stake in shares of Twist Bioscience Co. (NASDAQ:TWST) by 32.3% in the 4th quarter, HoldingsChannel reports. The firm owned 29,501 shares of the company’s stock after selling 14,091 shares during the quarter. Algert Global LLC’s holdings in Twist Bioscience were worth $1,371,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds also recently modified their holdings of the company. Barclays PLC raised its stake in shares of Twist Bioscience by 214.8% in the third quarter. Barclays PLC now owns 153,039 shares of the company’s stock valued at $6,913,000 after buying an additional 104,420 shares during the period. Avanza Fonder AB purchased a new stake in Twist Bioscience during the fourth quarter valued at about $1,059,000. Principal Financial Group Inc. boosted its position in Twist Bioscience by 67.5% during the third quarter. Principal Financial Group Inc. now owns 205,864 shares of the company’s stock worth $9,301,000 after purchasing an additional 82,953 shares during the period. Vanguard Group Inc. increased its stake in shares of Twist Bioscience by 3.4% in the fourth quarter. Vanguard Group Inc. now owns 5,807,183 shares of the company’s stock worth $269,860,000 after purchasing an additional 189,791 shares in the last quarter. Finally, Wells Fargo & Company MN lifted its stake in shares of Twist Bioscience by 34.5% during the 4th quarter. Wells Fargo & Company MN now owns 37,886 shares of the company’s stock valued at $1,761,000 after buying an additional 9,722 shares in the last quarter.

Twist Bioscience Price Performance

Shares of NASDAQ:TWST opened at $30.82 on Friday. Twist Bioscience Co. has a one year low of $30.72 and a one year high of $60.90. The company has a debt-to-equity ratio of 0.03, a current ratio of 4.96 and a quick ratio of 4.62. The firm has a market capitalization of $1.85 billion, a price-to-earnings ratio of -9.12 and a beta of 2.54. The company’s fifty day moving average price is $38.63 and its 200-day moving average price is $43.65.

Twist Bioscience (NASDAQ:TWST) last issued its quarterly earnings results on Monday, May 5th. The company reported ($0.66) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.56) by ($0.10). The firm had revenue of $92.79 million for the quarter, compared to the consensus estimate of $92.00 million. Twist Bioscience had a negative return on equity of 32.69% and a negative net margin of 59.76%. On average, equities research analysts anticipate that Twist Bioscience Co. will post -2.12 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

TWST has been the topic of a number of analyst reports. Guggenheim reissued a “buy” rating and set a $50.00 target price on shares of Twist Bioscience in a report on Tuesday. Barclays dropped their price objective on Twist Bioscience from $58.00 to $45.00 and set an “overweight” rating on the stock in a report on Thursday, April 10th. Robert W. Baird reduced their target price on Twist Bioscience from $54.00 to $44.00 and set an “outperform” rating for the company in a report on Tuesday. Scotiabank reissued an “outperform” rating on shares of Twist Bioscience in a report on Tuesday, February 4th. Finally, JPMorgan Chase & Co. decreased their target price on shares of Twist Bioscience from $40.00 to $33.00 and set an “underweight” rating on the stock in a report on Tuesday. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $50.40.

Insider Buying and Selling at Twist Bioscience

In related news, CEO Emily M. Leproust sold 2,402 shares of the stock in a transaction on Thursday, March 6th. The shares were sold at an average price of $40.91, for a total transaction of $98,265.82. Following the transaction, the chief executive officer now owns 662,692 shares of the company’s stock, valued at approximately $27,110,729.72. This trade represents a 0.36 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Paula Green sold 918 shares of the business’s stock in a transaction on Thursday, March 6th. The stock was sold at an average price of $40.91, for a total transaction of $37,555.38. Following the completion of the sale, the senior vice president now directly owns 130,912 shares of the company’s stock, valued at $5,355,609.92. This represents a 0.70 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 18,991 shares of company stock worth $742,654 over the last ninety days. Insiders own 3.01% of the company’s stock.

Twist Bioscience Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.